ScreenerHero

ARQT Arcutis Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · arcutis.com
24.17USD+1.05%Mkt Cap: 3.04B $P/E: 109.86

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the trea…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.04B USD
Enterprise Value2.88B USD
Revenue (TTM)463.98M USD
Gross Profit339.38M USD
Net Income (TTM)-16.14M USD
Revenue/Share3.60 USD
Last Price24.17 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees354
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)109.86
P/E (Forward)17.59
PEG—
EV/EBITDA78.96
EV/Revenue6.21
P/S6.48
P/B13.62
EPS (TTM)0.22
EPS (Forward)1.36
52W Range
16.5750% of range31.77
52W High31.77 USD
52W Low16.57 USD
Profitability
Gross Margin90.24%
Oper. Margin12.65%
EBITDA Margin7.87%
Profit Margin-4.29%
ROE-8.52%
ROA-3.73%
Growth
Revenue Growth59.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.63M USD
CapEx (TTM)10.69M USD
FCF Margin4.67%
FCF Yield0.71%
Net Debt-124.42M USD
Net Debt/EBITDA-3.41
Balance Sheet
Debt/Equity0.60
Current Ratio2.92
Quick Ratio2.46
Book Value/Sh1.76 USD
Cash/Share1.90 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)37.00 USD
Upside (mean)+53.1%
Target Range34.00 USD – 40.00 USD
34.00+53.1% to mean40.00
# Analysts7
Ownership
Shares Out.125.69M
Float93.82M
Insiders1.77%
Institutions108.73%
Short Interest
Short Ratio9.3d
Short % Float15.66%
Short % Out.14.69%
Shares Short18.46M
Short (prev mo.)14.72M
Technical
SMA 5025.65 (-5.8%)
SMA 20025.19 (-4.0%)
Beta1.58
S&P 52W Chg16.45%
Avg Vol (30d)2.64M
Avg Vol (10d)2.37M
Technical Indicators
RSI (14)42.3
MACD-0.1311
MACD Signal0.0541
MACD Hist.-0.1852
BB Upper28.02 USD
BB Middle25.31 USD
BB Lower22.60 USD
BB Width21.44%
ATR (14)1.212 USD
Vol Ratio (20d)0.53x